fluprednisolone has been researched along with Uveitis, Anterior in 10 studies
Fluprednisolone: A synthetic glucocorticoid with anti-inflammatory properties.
Uveitis, Anterior: Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.
Excerpt | Relevance | Reference |
---|---|---|
"Difluprednate given 2 or 4 times a day cleared postoperative inflammation and reduced pain rapidly and effectively." | 9.14 | Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. ( Cooke, DL; Crockett, RS; Korenfeld, MS; Silverstein, SM; Vogel, R, 2009) |
"To describe the use of topical difluprednate for the treatment of uveitic macular edema." | 7.83 | Topical difluprednate monotherapy for uveitic macular edema. ( Forooghian, F; Symes, RJ, 2016) |
" Safety included evaluation of adverse events." | 6.82 | Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. ( Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016) |
"In this high-dose pulsed-therapy regimen, difluprednate reduced inflammation more effectively than prednisolone acetate, resulting in more rapid return of vision." | 5.15 | A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. ( Donnenfeld, ED; Fiore, J; Gobbo, A; Holland, EJ; Perry, HD; Prince, J; Sandoval, HP; Shull, ER; Solomon, KD, 2011) |
"Difluprednate given 2 or 4 times a day cleared postoperative inflammation and reduced pain rapidly and effectively." | 5.14 | Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. ( Cooke, DL; Crockett, RS; Korenfeld, MS; Silverstein, SM; Vogel, R, 2009) |
"To describe the use of topical difluprednate for the treatment of uveitic macular edema." | 3.83 | Topical difluprednate monotherapy for uveitic macular edema. ( Forooghian, F; Symes, RJ, 2016) |
" Safety included evaluation of adverse events." | 2.82 | Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. ( Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016) |
" Difluprednate provides effective treatment for anterior uveitis and requires less frequent dosing than prednisolone acetate." | 2.75 | Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. ( Crockett, RS; Davanzo, R; Flynn, TE; Foster, CS; McLeod, K; Vogel, R, 2010) |
"Difluprednate 0." | 1.36 | Intraocular pressure elevation from topical difluprednate use. ( Meehan, K; Sowka, J; Vollmer, L, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 9 (90.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sheppard, JD | 1 |
Toyos, MM | 1 |
Kempen, JH | 1 |
Kaur, P | 1 |
Foster, CS | 3 |
Abu Samra, K | 1 |
Valdes-Navarro, M | 1 |
Lee, S | 1 |
Swan, R | 1 |
Anesi, SD | 1 |
Symes, RJ | 1 |
Forooghian, F | 1 |
Wilson, ME | 1 |
O'Halloran, H | 1 |
VanderVeen, D | 1 |
Roarty, J | 1 |
Plager, DA | 1 |
Markwardt, K | 1 |
Gedif, K | 1 |
Lambert, SR | 1 |
Korenfeld, MS | 1 |
Silverstein, SM | 1 |
Cooke, DL | 1 |
Vogel, R | 2 |
Crockett, RS | 2 |
Davanzo, R | 1 |
Flynn, TE | 1 |
McLeod, K | 1 |
Meehan, K | 1 |
Vollmer, L | 1 |
Sowka, J | 1 |
Donnenfeld, ED | 1 |
Holland, EJ | 1 |
Solomon, KD | 1 |
Fiore, J | 1 |
Gobbo, A | 1 |
Prince, J | 1 |
Sandoval, HP | 1 |
Shull, ER | 1 |
Perry, HD | 1 |
Oltra, EZ | 1 |
Morris, C | 1 |
Birnbaum, AD | 1 |
Tessler, HH | 1 |
Goldstein, DA | 1 |
Liu, MP | 1 |
Hwang, FS | 1 |
Dunn, JP | 1 |
Stark, WJ | 1 |
Bower, KS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis[NCT01201798] | Phase 3 | 111 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
A Prospective, Multi-center, Controlled, Double-blind Study to Evaluate the Efficacy and Tolerability of a Steroid/Antibiotic Associated Treatment Following Cataract Extraction by Means of Phaco-emulsification[NCT02973880] | Phase 3 | 180 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery[NCT00429923] | Phase 3 | 219 participants (Actual) | Interventional | Completed | |||
A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery[NCT00430092] | Phase 3 | 219 participants (Actual) | Interventional | Completed | |||
[NCT00501579] | Phase 3 | 0 participants | Interventional | Completed | |||
A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal [NCT01244334] | Phase 4 | 52 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Lack of efficacy was defined as those subjects who discontinued study participation either due to treatment failure or an adverse event with a preferred term of iridocyclitis, iritis, uveitis, or vitritis. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Time to Event
Intervention | Percentage of subjects (Number) |
---|---|
Durezol | 0 |
Pred Forte | 14.9 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = ≤ 1 cell count; 1 = 2 to 10 cell count; 2 = 11 to 20 cell count; 3 = 21 to 50 cell count; and 4 = > 50 cell count. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 21, Day 28, Day 35, Day 42
Intervention | Units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline (Day 0) | Day 3 | Day 7 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 2.6 | -1.1 | -1.8 | -2.4 | -2.3 | -2.3 | -2.3 |
Pred Forte | 2.6 | -1.0 | -1.6 | -2.1 | -2.1 | -2.1 | -2.1 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = ≤ 1 cell count; 1 = 2 to 10 cell count; 2 = 11 to 20 cell count; 3 = 21 to 50 cell count; and 4 = > 50 cell count. (NCT01201798)
Timeframe: Baseline (Day 0), Day 14
Intervention | Units on a scale (Mean) | |
---|---|---|
Baseline (Day 0) | Day 14 | |
Durezol | 2.6 | -2.2 |
Pred Forte | 2.6 | -2.0 |
Anterior chamber flare (protein escaping from dialated vessels) was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline (Day 0) | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 2.2 | -1.1 | -1.6 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
Pred Forte | 2.3 | -1.2 | -1.6 | -1.9 | -2.0 | -2.0 | -2.0 | -2.0 |
The following signs were each graded on a 0 - 3 scale (0 = absent; 1 = mild; 2 = moderate; 3 = severe): posterior synechia, hypopyon, limbal injection, and keratic precipitates. Peripheral synechia was graded by the combined number of clock hours affected (0 = absent; 1 = < 3 hrs; 2 = 3-6 hours; 3 = > 6 hours). The total sign score was calculated as the sum of the 5 individual sign scores, the anterior chamber cell grade and the anterior chamber flare grade. The minimum/best total sign score was 0, and the maximum/worst total sign score was 23. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline (Day 0) | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 7.1 | -3.5 | -5.2 | -6.1 | -6.5 | -6.4 | -6.3 | -6.2 |
Pred Forte | 7.3 | -3.6 | -5.0 | -5.8 | -6.2 | -6.2 | -6.2 | -6.3 |
The following symptoms were each graded by the subject according to a 0-100 visual analog scale (VAS) using a mark on a 100 mm line (0 = absent, 100 = maximal): eye pain, photophobia, blurred vision, and lacrimation. The total symptom score was calculated as the sum of the 4 individual symptom scores. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline (Day 0) | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 186.7 | -88.4 | -108.2 | -133.3 | -138.8 | -140.1 | -143.9 | -146.2 |
Pred Forte | 203.2 | -88.4 | -123.8 | -137.4 | -149.5 | -152.4 | -147.3 | -155.5 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and recorded based on actual cell count. Anterior chamber flare (protein escaping from dialated vessels) was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Percentage of subjects (Number) | ||||||
---|---|---|---|---|---|---|---|
Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 13.0 | 41.3 | 78.3 | 82.6 | 80.4 | 82.6 | 80.4 |
Pred Forte | 14.9 | 40.4 | 61.7 | 76.6 | 76.6 | 76.6 | 78.7 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and recorded based on actual cell count. Proportion is reported as a percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Percentage of subjects (Number) | ||||||
---|---|---|---|---|---|---|---|
Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 13.0 | 21.7 | 52.2 | 73.9 | 73.9 | 69.6 | 69.6 |
Pred Forte | 2.1 | 21.3 | 38.3 | 48.9 | 63.8 | 63.8 | 68.1 |
As assessed by the investigator during slit lamp examination. Anterior chamber cell grade was graded on a 5-point scale, with 0 = no cells; 1 = 1 to 10 cells; 2 = 11 to 20 cells; 3 = 21 to 50 cells; and 4 = more than 50 cells. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Percentage of subjects (Number) | ||||||
---|---|---|---|---|---|---|---|
Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 50.0 | 87.0 | 93.5 | 93.5 | 93.5 | 93.5 | 91.3 |
Pred Forte | 57.4 | 80.9 | 85.1 | 89.4 | 87.2 | 85.1 | 85.1 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = ≤ 1 cell count; 1 = 2 to 10 cell count; 2 = 11 to 20 cell count; 3 = 21 to 50 cell count; and 4 = > 50 cell count. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
Intervention | Percentage of subjects (Number) | ||||||
---|---|---|---|---|---|---|---|
Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
Durezol | 15.2 | 34.8 | 65.2 | 84.8 | 80.4 | 78.3 | 76.1 |
Pred Forte | 6.4 | 25.5 | 55.3 | 63.8 | 70.2 | 70.2 | 74.5 |
"Measured on a 0 to 4 scale: 0 is ≤ 1 cell; 1 is 2-10 cells; 2 is 11-20 cells; 3 is 21-50 cells; 4 is > 50 cells." (NCT00429923)
Timeframe: Day 8 (QID)
Intervention | participants (Number) |
---|---|
Proportion of subjects w/AC cell grade=0 on Day 8 | |
Difluprednate 0.05% BID | 0 |
Difluprednate 0.05% QID | 19 |
Placebo | 13 |
"Measured on a 0 to 4 scale: 0 is ≤ 1 cell; 1 is 2-10 cells; 2 is 11-20 cells; 3 is 21-50 cells; 4 is > 50 cells." (NCT00430092)
Timeframe: Day 8 (QID)
Intervention | participants (Number) |
---|---|
Proportion of Subjects w/AC cell grade=0 on Day 8 | |
Difluprednate 0.05% BID | 0 |
Difluprednate 0.05% QID | 18 |
Placebo | 7 |
5 trials available for fluprednisolone and Uveitis, Anterior
Article | Year |
---|---|
Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anterior Chamber; Anti-Inflammator | 2014 |
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Administration, Topical; Aphakia, Postcataract; Cataract; Cataract Extraction; Child, Preschool; Dou | 2016 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis.
Topics: Adult; Anterior Chamber; Anti-Inflammatory Agents; Emulsions; Female; Fluprednisolone; Glucocorticoi | 2010 |
A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery.
Topics: Aged; Aged, 80 and over; Cell Count; Cornea; Corneal Edema; Double-Blind Method; Endothelium, Cornea | 2011 |
5 other studies available for fluprednisolone and Uveitis, Anterior
Article | Year |
---|---|
A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Fluprednisolone; Glucoc | 2016 |
Topical difluprednate monotherapy for uveitic macular edema.
Topics: Administration, Topical; Adult; Female; Fluprednisolone; Glucocorticoids; Humans; Macular Edema; Mal | 2016 |
Intraocular pressure elevation from topical difluprednate use.
Topics: Administration, Topical; Black or African American; Emulsions; Female; Fluprednisolone; Glucocortico | 2010 |
Chronic anterior uveitis in common variable immunodeficiency.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Child; Chronic Disease; C | 2011 |
Hypopyon uveitis following LASIK in a patient with ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Astigmatism; Colitis, Ulcerative; Fluprednisolone; Gl | 2012 |